Similarly, results from a phase 2 study using sirolimus (rapamycin), an mTOR inhibitor, in NF1 patients with plexiform neurofibroma, did not report any regression of the lesions [162]. This evidence concerns the gene MTOR and neurofibromatosis type 1.